TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2406936121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Wen-Long Ye und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Suzhou Medical College of Soochow University, Soochow University, Suzhou 215123, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Autophagy, Phenylurea Compounds, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, JST | Natural Science Foundation of Jiangsu Province (Jiangsu Natural Science Foundation), Suzhou Medical Key Supported Discipline.
Abstract (Originalsprache)
Kirsten rat sarcoma virus (KRAS) mutation is associated with malignant tumor transformation and drug resistance. However, the development of clinically effective targeted therapies for KRAS-mutant cancer has proven to be a formidable challenge. Here, we report that tripartite motif-containing protein 21 (TRIM21) functions as a target of extracellular signal-regulated kinase 2 (ERK2) in KRAS-mutant colorectal cancer (CRC), contributing to regorafenib therapy resistance. Mechanistically, TRIM21 directly interacts with and ubiquitinates v-myc avian myelocytomatosis viral oncogene homolog (c-Myc) at lysine 148 (K148) via K63-linkage, enabling c-Myc to be targeted to the autophagy machinery for degradation, ultimately resulting in the downregulation of enolase 2 expression and inhibition of glycolysis. However, mutant KRAS (KRAS/MT)-driven mitogen-activated protein kinase (MAPK) signaling leads to the phosphorylation of TRIM21 (p-TRIM21) at Threonine 396 (T396) by ERK2, disrupting the interaction between TRIM21 and c-Myc and thereby preventing c-Myc from targeting autophagy for degradation. This enhances glycolysis and contributes to regorafenib resistance. Clinically, high p-TRIM21 (T396) is associated with an unfavorable prognosis. Targeting TRIM21 to disrupt KRAS/MT-driven phosphorylation using the antidepressant vilazodone shows potential for enhancing the efficacy of regorafenib in treating KRAS-mutant CRC in preclinical models. These findings are instrumental for KRAS-mutant CRC treatment aiming at activating TRIM21-mediated selective autophagic degradation of c-Myc.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Suzhou Medical College of Soochow University, Soochow University, Suzhou 215123, China.
- Department of Pathology, The Fourth Affiliated Hospital of Soochow University, Soochow University, Suzhou 215000, China.
- Department of General Surgery, The Affiliated Zhangjiagang Hospital of Soochow University, Soochow University, Suzhou 215600, China.
- Department of Bioinformatics, Suzhou Medical College of Soochow University, Soochow University, Suzhou 215123, China.
- Cancer Institute, Suzhou Medical College of Soochow University, Soochow University, Suzhou 215123, China.
ORCID-Profile: Xiao-Qin Yang, Yu Song, Hua Wu
Förderung
- National Natural Science Foundation of China
- JST | Natural Science Foundation of Jiangsu Province (Jiangsu Natural Science Foundation)
- Suzhou Medical Key Supported Discipline
Zitieren
APA
Ye, W. L., Huang, L., Yang, X. Q., Wan, S., Gan, W. J., Yang, Y., He, X. S., Liu, F., Guo, X., Liu, Y. X., Hu, G., Li, X. M., Shi, W. Y., He, K., Wu, Y. Y., Wu, W. X., Lu, J. H., Song, Y., Qu, C. J., & Wu, H. (2024). TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2406936121
Vancouver
Ye WL, Huang L, Yang XQ, Wan S, Gan WJ, Yang Y, et al. TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2406936121
BibTeX
@article{Ye2024,
author = {Ye, Wen-Long and Huang, Long and Yang, Xiao-Qin and Wan, Shan and Gan, Wen-Juan and Yang, Yun and He, Xiao-Shun and Liu, Feng and Guo, Xin and Liu, Yi-Xuan and Hu, Guang and Li, Xiu-Ming and Shi, Wei-Yi and He, Kuang and Wu, Yue-Yue and Wu, Wen-Xin and Lu, Jun-Hou and Song, Yu and Qu, Chen-Jiang and Wu, Hua},
title = {TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2406936121}
}
EUVIMED